文献速递其他结缔组织病

肌束周肌纤维蛋白酶体活性增强是皮肌炎标志,抑制该通路在临床前模型中有效

Enhanced proteasome activity in perifascicular myofibres is a hallmark of dermatomyositis and its inhibition is efficient in preclinical models.
PubMed 文献 · Ann Rheum Dis · 2025-10-07

研究对7例未经治疗早期皮肌炎(DM)、6例其他炎性肌病和5例无神经肌肉疾病患者的微切割肌束周及肌束内肌纤维行RNA测序,发现蛋白酶体通路上调是DM肌束周肌纤维的标志。计算药物重定位分析提名伊沙佐米为最具治疗潜力候选,细胞及动物实验显示其可预防IFN-β诱导的DM样病变并改善实验性肌炎小鼠肌力与血清肌酸激酶。

要点

  • 肌束周肌纤维蛋白酶体通路上调是皮肌炎的分子标志。
  • 伊沙佐米在体外可预防IFN-β诱导的肌萎缩、MHC-I表达及线粒体功能障碍。
  • 伊沙佐米治疗实验性肌炎小鼠可恢复肌力并使血清肌酸激酶正常化。

核心结论

  • 肌束周肌纤维蛋白酶体活性增强是皮肌炎(DM)的标志,抑制该活性在临床前模型中有效,可能成为DM的新治疗策略。

研究设计与样本

  • 对7例未经治疗早期DM(症状<6个月)、6例其他炎性肌病和5例无神经肌肉疾病患者的微切割肌束周及肌束内肌纤维行RNA测序。
  • 在验证队列行免疫组化,并在人肌管及实验性肌炎(EM)小鼠等细胞和动物临床前模型中验证候选分子。

主要发现

  • 微切割肌纤维转录组分析显示蛋白酶体通路上调在肌束周肌纤维占优势,是DM的标志。
  • 免疫组化验证队列显示DM患者肌束周区域肌纤维胞质主要表达β5i(由PSMB8编码),该区域也主要表达MxA和HLA-I。
  • 人肌管实验显示干扰素(IFN)-β增强肌纤维中蛋白酶体催化亚基β5i表达及胰凝乳蛋白酶样活性。
  • 基于DM肌束周肌纤维转录组特征的计算药物重定位分析将蛋白酶体抑制剂伊沙佐米列为最具治疗潜力的药物。
  • 伊沙佐米在EM小鼠中恢复肌力并正常化血清肌酸激酶,肌肉ISG表达未变,但肌膜MHC-I表达消失、肌纤维大小变异性正常化、炎性浸润减少。

关键数值与推荐

  • 人肌管中伊沙佐米预防IFN-β诱导的DM样病变(萎缩、MHC-I表达及线粒体功能障碍),且不影响干扰素刺激基因(ISG)表达。

临床怎么用

  • 基于上述临床前证据,抑制蛋白酶体活性可能代表皮肌炎的一种新治疗策略。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to characterise the molecular pathways underpinning perifascicular muscle fibre alterations to identify repositionable molecules for dermatomyositis (DM) treatment, and validate potential candidates in preclinical models. METHODS: RNA-sequencing was performed to determine the transcriptome of microdissected peri- and endofascicular myofibres from 7 patients with untreated and early DM (symptoms <6 months), 6 with other inflammatory myopathies and 5 without neuromuscular disease. The molecular pathways characterising DM perifascicular fibres were determined and used to explore databases of repositionable drugs. The top candidate molecule was validated in cellular and animal preclinical models. RESULTS: Microdissected myofibre transcriptomic analysis revealed that upregulation of the proteasome pathway, prevailing in perifascicular myofibres, is a hallmark of DM. Immunostaining experiments conducted in a validation cohort showed that in patients with DM, β5i (encoded by PSMB8) was predominantly expressed in the cytoplasm of muscle fibres within the perifascicular region, which also predominantly expressed MxA and HLA-I. Experiments in human myotubes showed that interferon (IFN)-β enhances the expression of proteasome catalytic subunit β5i and chymotrypsin-like activity in myofibres. Computational drug repurposing analysis based on the DM perifascicular myofibre transcriptomic signature identified ixazomib (a proteasome inhibitor) as the drug with the highest therapeutic potential. In human myotubes, ixazomib prevented IFN-β-induced DM-like lesions (atrophy, major histocompatibility complex class I [MHC-I] expression and mitochondrial dysfunctions) without impacting the expression of interferon-stimulated genes (ISGs). Moreover, experimental myositis (EM) mice treated with ixazomib recovered muscle strength and normalised serum creatine kinase levels. While ISG expression was unchanged in muscles of ixazomib-treated EM mice, sarcolemmal MHC-I expression was abolished, myofibre size variability was normalised, and inflammatory infiltrate was decreased. CONCLUSIONS: Enhanced proteasome activity in perifascicular myofibres is a hallmark of DM; its inhibition, deemed effective in preclinical models, may represent a new therapeutic strategy for this disease.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Debrut L, Giannini M, Quiring G, et al. Enhanced proteasome activity in perifascicular myofibres is a hallmark of dermatomyositis and its inhibition is efficient in preclinical models. Ann Rheum Dis. 2025. PMID: 41058389. doi:10.1016/j.ard.2025.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。